Published in J Urol on February 01, 2006
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol (2010) 2.26
Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol (2009) 1.87
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol (2009) 0.92
5-α reductase inhibitors and prostate cancer prevention: where do we turn now? BMC Med (2011) 0.89
Prostate size and adverse pathologic features in men undergoing radical prostatectomy. Urology (2014) 0.88
Epidemiology of prostate cancer and treatment remarks. World J Radiol (2012) 0.87
PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials (2015) 0.87
5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med (2014) 0.85
Gleason grading controversies: what the chemoprevention trials have taught us. Can Urol Assoc J (2009) 0.81
Predictors of Gleason score upgrading in patients with prostate biopsy Gleason score ≤6. Can Urol Assoc J (2014) 0.81
Temporal changes in the pathologic assessment of prostate cancer. J Natl Cancer Inst Monogr (2012) 0.80
PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. Can Urol Assoc J (2007) 0.77
Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores. World J Urol (2014) 0.76
Diagnosing prostate cancer: through a glass, darkly. J Urol (2006) 0.76
Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value. Clin Lung Cancer (2015) 0.76
Refining prostate biopsy strategies. J Urol (2006) 0.75
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2010) 6.01
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 4.61
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol (2011) 3.51
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol (2008) 3.02
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Training carers of stroke patients: randomised controlled trial. BMJ (2004) 2.95
Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
Therapeutic options following orchiectomy for stage I seminoma. Oncology (Williston Park) (2009) 2.67
The natural history of incidentally detected small renal masses. Cancer (2004) 2.57
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2013) 2.53
The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol (2002) 2.48
Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol (2007) 2.33
Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol (2009) 2.33
Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol (2011) 2.29
Clinical practice. Small renal mass. N Engl J Med (2010) 2.27
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
The concept and trajectory of "operative competence" in surgical training. Can J Surg (2006) 2.15
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. Urology (2011) 2.07
Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst (2012) 2.06
Longer wait times increase overall mortality in patients with bladder cancer. J Urol (2009) 2.05
VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol (2006) 2.03
Differences in stroke subtypes between black and white patients with stroke: the South London Ethnicity and Stroke Study. Circulation (2007) 2.01
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol (2007) 1.94
Digital imaging in pathology: whole-slide imaging and beyond. Annu Rev Pathol (2012) 1.89
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol (2010) 1.87
IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys (2005) 1.84
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab (2013) 1.81
Management of stage T1 tumors of the bladder: International Consensus Panel. Urology (2005) 1.81
Is there an optimal comorbidity index for prostate cancer? Cancer (2008) 1.80
Health information quality on the internet in urological oncology: a multilingual longitudinal evaluation. Urology (2009) 1.78
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res (2007) 1.75
Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial. Stroke (2003) 1.74
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Unintended consequences of laparoscopic surgery on partial nephrectomy for kidney cancer. J Urol (2009) 1.71
A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol (2006) 1.71
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol (2003) 1.70
Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol (2008) 1.66
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66
Fellow or foe: the impact of fellowship training programs on the education of Canadian urology residents. Can Urol Assoc J (2008) 1.62
Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus. Urology (2013) 1.58
Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology (2007) 1.58
Laparoscopic partial nephrectomy: 3-year followup. J Urol (2006) 1.57
Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol (2010) 1.57
Solitary extramedullary plasmacytoma of the head and neck--long-term outcome analysis of 68 cases. Head Neck (2008) 1.56
Population based survival data on urachal tumors. J Urol (2006) 1.55
Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Can Urol Assoc J (2010) 1.55
Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys (2005) 1.54
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54
Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol (2008) 1.53
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst (2007) 1.53
Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med (2007) 1.53
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53
Higher surgeon and hospital volume improves long-term survival after radical cystectomy. Cancer (2013) 1.52